|
Market Closed -
TEL AVIV STOCK EXCHANGE
10:24:24 2026-10-15 EDT
|
5-day change | 1st Jan Change | ||
| 2,435.00 ILa | +3.62% |
|
+2.66% | +7.74% |
| 10-06 | Kamada Launches Ustekinumab, Enoxaparin Biosimilars in Israel | MT |
| 10-06 | Kamada Ltd. Announces Expansion of Biosimilars Portfolio with Launch of Two Additional Products in Israel | CI |
| Market Cap | 1.41B 0 453M 404M 376M 342M 643M 42.89B 654M 4.51B 1.77B 22.38B 1.7B 1.66B 71.61B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 1.41B 0 453M 404M 376M 342M 643M 42.89B 654M 4.51B 1.77B 22.38B 1.7B 1.66B 71.61B | EV / Sales 2026 * |
2.31x | EV / Sales 2027 * | 2.05x |
| Free-Float |
54.72% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
TEL AVIV STOCK EXCHANGE
| KMDA | Delayed | |
Nasdaq
| KMDA | Delayed | |
|
CBOE
| KMDA | Real-time |
Last Transcript: Kamada Ltd.
| 1 day | +3.62% | ||
| 1 week | +2.66% | ||
| Current month | -8.11% | ||
| 1 month | -0.25% | ||
| 3 months | +13.20% | ||
| 6 months | -3.79% | ||
| Current year | +7.74% |
| 1 week | 2,300 |  | 2,476 |
| 1 month | 2,300 | | 2,698 |
| Current year | 2,013 | | 2,890 |
| 1 year | 1,956 | | 2,890 |
| 3 years | 1,685 | | 3,045 |
| 5 years | 1,309 | | 3,045 |
| 10 years | 1,309 | | 4,500 |
| Manager | Title | Age | Since |
|---|---|---|---|
Amir London
CEO | Chief Executive Officer | 58 | 2015-06-30 |
Chaime Orlev
DFI | Director of Finance/CFO | 56 | 2017-12-30 |
Eran Nir
COO | Chief Operating Officer | 54 | 2016-10-31 |
| Director | Title | Age | Since |
|---|---|---|---|
David Tsur
BRD | Director/Board Member | 75 | 1990-12-12 |
Leon Recanati
CHM | Chairman | 77 | 2013-03-06 |
| Chairman | 55 | 2020-08-11 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/14/26 | Exercice | VP Quality | 61,323 | 0.1063% | ||
| 9/14/26 | Sell | Founder | -22,827 | 0.0396% | ||
| 9/14/26 | Exercice | General Counsel | 23,459 | 0.0407% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.62% | +2.66% | +10.63% | +33.21% | 438M | |
| +3.55% | +7.01% | +51.42% | +105.45% | 1,077B | |
| -0.25% | -1.25% | +32.49% | +61.48% | 612B | |
| +0.59% | +4.03% | +25.28% | +91.54% | 501B | |
| -1.48% | +1.97% | +72.62% | +39.59% | 364B | |
| +2.37% | +7.66% | +33.65% | +48.87% | 353B | |
| +2.64% | +6.95% | +21.01% | +43.85% | 278B | |
| +3.24% | +6.78% | +0.43% | +15.71% | 251B | |
| +1.86% | +6.53% | +45.98% | +52.77% | 230B | |
| +2.49% | +6.98% | +33.03% | +102.67% | 190B | |
| Average | +1.86% | +3.52% | +32.65% | +59.51% | 385.7B | |
| Weighted average by Cap. | +1.74% | +4.12% | +38.65% | +71.71% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 609M 0 196M 175M 163M 148M 278M 18.57B 283M 1.95B 765M 9.69B 736M 720M 31.01B | 685M 0 221M 197M 183M 167M 314M 20.92B 319M 2.2B 861M 10.91B 829M 811M 34.93B |
| Net income | 83.39M 0 26.87M 23.99M 22.29M 20.28M 38.15M 2.55B 38.84M 268M 105M 1.33B 101M 98.7M 4.25B | 101M 0 32.65M 29.14M 27.09M 24.64M 46.35M 3.09B 47.19M 325M 127M 1.61B 123M 120M 5.16B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-15 | ILA 2,435.00 | +3.62% | 89,797 |
| 26-10-14 | ILA 2,350.00 | -1.34% | 40,153 |
| 26-10-13 | ILA 2,382.00 | -2.14% | 44,934 |
| 26-10-12 | ILA 2,434.00 | -1.38% | 38,487 |
| 26-10-09 | ILA 2,468.00 | +4.05% | 63,555 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- KMDA Stock
Select your edition
All financial news and data tailored to specific country editions
